EN

Skirmishing Aggressive Cancers with Simultaneous Caspase 3 & 9 Activation and Cyclin D2 & B1 and MMP-9 Suppression: Pro-Apoptopic Therapy

A Dual Punch via elevating Benevolent Apoptosis while suppressing Malignant Proliferative Factors facilitates a Synergy that may overrule Classical Chemotherapy and may provide the much needed boost to Underperforming But Promising Sole Immunotherapic Approach. An effective Adjuvant or only pragmatic and Appliable Result Producing Alternative when it comes to Battling with the paracrinal / autocrinal calamity of our time: CANCER.

SCIENTIFIC ADVANCES

A COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS

Technical Field

The invention relates to a composition formed for the use of 20-O-B-D-glucopyranosyl-20(S)-protopanaxatriol and the derivatives thereof in the treatment of the malignant tumors.

State of the Art

Tumor, or tumour, is the name given to any lump generally developing in the tissues, and in more frequently used terms, it is the name given to the benign or malign mass of neoplasia tissue. Tumors have 3 basic properties: Tumors grow without any purpose. The reason is that they have acquired autonomy. Unlike the normal tissues, there is no limit for the growth of the tumors. In other words, they grow limitlessly. The growth of the tumors may not be fully controlled by any control mechanism (apoptosis, etc.). As a result, the tumors grow in an uncontrolled manner.
Injection of powerful pro-apoptotic immune factors (tnf-a derivatives, interferon gamma) into the tumors, radiotherapy, injection of the chemotherapeutic drugs directly into the tumor, injection of the ribonucleotide reductase suppressing agents

directly into the tumors and removal of tumors via surgical intervention may be listed as the examples of the current treatments for the solid tumors.

The invention no. US19980193354 entitled “Certain substituted caprolactams, pharmaceutical compositions containing the same and their use in treating the tumors” relates to certain substituted caprolactam compounds, pharmaceutical compositions containing said compounds, the use of said compounds in treating the tumors and a process for making said compounds.

The invention no. WO2005CN00111 entitled “Novel use of recombinant adenovirus-P53 agent for the treatment of the tumor patients” discloses a recombinant p53 adenovirus, which is able to reduce the side effects, including but not limited to the side effects of the antitumor chemotherapy and the radiotherapy. The invention also discloses that the recombinant p53 adenovirus may alone enable the recovery of the blood cell count, liver function and kidney function in the tumor patients, and may accordingly allow the improvement in the life quality, increase in the appetite, better mental health and the like in the tumor patients.

As a result, the presence of the need for a composition for use in treating the malignant tumors and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

Object of the Invention

In order to eliminate the disadvantages of the state of the art, an object of the invention is to prevent the cell division by increasing the expression of AMPK (AMP-activated protein kinase) and by disrupting the mineral balance owing to the ability to trigger the Ca(+2) calcium over-load for the tumors.

Another object of the invention is to permanently destroy the ability of cell division and the ability of the tumor to effectively synthesize cancerous cells, owing to the cytoplasmic stress induced.

Another object of the invention is to trigger the death of the cancerous cells and reduce the cell viability, owing to the ability to trigger the early cell death.

Another object of the invention is to trigger the sub-G1 accumulation in the cancerous cells and induce the nucleus condensation, thereby causing the cell to lose its entire function.

Another object of the invention is to disrupt the element and mineral balance of the tumor and disrupt the endogenous homeostasis of the tumor cells by inducing the protein kinase like endoplasmic reticulum kinase phosphorylation and eukaryotic

initiation factor 2-alpha phosphorylation.

In order to achieve the aforesaid advantages, the invention is a composition for use in treating the malignant tumors, said composition being obtained by the components selected from the group comprising 20-O-B-D-glucopyranosyl-20(S)-protopanaxatriol, 20-O-B-D-glucopyranosyl-20(S)-B-D-protopanaxatriol, and other derivatives. Here we disclose all at Part 2.

Contributor

Contributed by:
Mas Pharmaceuticals

Turkey

Contact:
Erdal Can Alkoclar (Mr)
See more articles from this contributor

Last update: 5 August 2019
Record number: 125722

Permalink: https://cordis.europa.eu/article/id/125722-skirmishing-aggressive-cancers-with-simultaneous-caspase-3-9-activation-and-cyclin-d2-b1-and-